A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis. This is the ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May ...

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...

The announcement comes as part of WHO’s broader effort to reduce child mortality, particularly in low- and middle-income ...

June 2, 2025 - Last Friday, the World Health Organization (WHO) published its first-ever position paper on immunization ...

Universal immunisation with nirsevimab significantly reduces hospitalizations and paediatric intensive care admissions for ...

The World Health Organization (WHO) has published its first ever position paper on immunization against respiratory syncytial ...

RSV infections in children needing primary care cause high economic impact due to outpatient costs and parental work absences ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the ...

The study authors say flu or RSV may increase the risk of S pneumoniae infection by damaging the bronchi and lung epithelium, ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...